Clinical Trials Logo

Primary Mitochondrial Myopathy clinical trials

View clinical trials related to Primary Mitochondrial Myopathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT05267574 Terminated - Clinical trials for Primary Mitochondrial Myopathy

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

Start date: February 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This study is designed to evaluate the long-term safety and tolerability of REN001 administered once daily to subjects with PMM due to mitochondrial DNA mutations (mtDNA-PMM) or nuclear DNA mutations (nDNA-PMM). Subjects with mtDNA mutations will have previously completed Study REN001-201 or participated in Study REN001-101. Subjects with nDNA mutations who enroll in this study will be REN001- naïve.

NCT ID: NCT04641962 Active, not recruiting - Clinical trials for Primary Mitochondrial Myopathy

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

MOUNTAINSIDE
Start date: May 17, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the phase 2 portion of this study is to select a biologically-active ASP0367 dose level by pharmacokinetic (PK) and pharmacodynamic (PD) evaluation. The phase 2 portion of this study will also assess the safety and tolerability of ASP0367. The purpose of the phase 3 portion of this study is to assess the effect of ASP0367 on functional improvement relative to placebo and will also assess the safety and tolerability of ASP0367 relative to placebo. The phase 3 portion of this study will also assess the effect of ASP0367 on functional improvement and fatigue relative to placebo and will assess the effect of ASP0367 in overall participant functioning relative to placebo.

NCT ID: NCT04535609 Completed - Clinical trials for Primary Mitochondrial Myopathy

An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

STRIDE
Start date: May 21, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, parallel group, multi-centre, study designed to investigate the efficacy and safety of REN001 administered once daily over a 24-week period to patients with PMM.

NCT ID: NCT03862846 Terminated - Clinical trials for Primary Mitochondrial Myopathy

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Start date: May 10, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess REN001 safety in subjects with primary mitochondrial myopathy

NCT ID: NCT03323749 Terminated - Clinical trials for Primary Mitochondrial Myopathy

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

MMPOWER-3
Start date: October 9, 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter phase 3 randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety and efficacy of daily subcutaneous injections of elamipretide in subjects with primary mitochondrial myopathy. This will be followed by an open-label treatment extension.